Beyond analysts' top -and-bottom-line estimates for Merit Medical (MMSI), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Merit Medical (MMSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MMSI launches the Ventrax Delivery System, enhancing pulmonary access procedures with improved control, precision, and efficiency for interventionalists.
Merit Medical (MMSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Merit Medical's strong product portfolio raises optimism about the stock.
MMSI unveils 12-month efficacy data for WRAPSODY CIE, highlighting its advanced technology in vascular access maintenance and potential to improve patient outcomes.
Merit Medical continues to outperform, with the share price supported by on-target financial results, incremental M&A, and positive clinical data. The company's Wrapsody stent graft showed almost best-case clinical efficacy, positioning it to capture significant market share in dialysis graft occlusion procedures. Recent acquisitions, including EsophyX Z+ and Cook Medical's lead management portfolio, enhance Merit's product portfolio and offer longer-term synergies.
Merit Medical aims to improve care for vulnerable premature infants by evaluating the safety and efficacy of the Bloom Micro Occluder System for treating PDA in the specified patient pool.
Merit Medical Systems, Inc. (MMSI) Q4 2024 Earnings Call Transcript
While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Merit Medical (MMSI) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.81 per share a year ago.
Evaluate the expected performance of Merit Medical (MMSI) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.